News articles about Danaher (NYSE:DHR) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Danaher earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned media coverage about the conglomerate an impact score of 47.2299319828731 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment’s analysis:

DHR has been the topic of a number of analyst reports. J P Morgan Chase & Co restated an “overweight” rating and issued a $95.00 price target on shares of Danaher in a research note on Friday, September 8th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a research note on Thursday, October 5th. Morgan Stanley restated an “overweight” rating and issued a $95.00 price target (up from $86.00) on shares of Danaher in a research note on Friday, October 6th. Cowen restated a “buy” rating and issued a $90.00 price target on shares of Danaher in a research note on Wednesday, October 4th. Finally, Credit Suisse Group lifted their price target on Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research note on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Danaher currently has a consensus rating of “Buy” and a consensus price target of $94.18.

Danaher (DHR) traded up $0.36 on Monday, reaching $94.36. The company’s stock had a trading volume of 2,960,657 shares, compared to its average volume of 2,628,209. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. The stock has a market capitalization of $65,386.87, a P/E ratio of 24.16, a price-to-earnings-growth ratio of 2.24 and a beta of 1.02. Danaher has a one year low of $77.66 and a one year high of $94.84.

Danaher (NYSE:DHR) last posted its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.05. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a return on equity of 11.29% and a net margin of 13.36%. Danaher’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.87 earnings per share. equities analysts anticipate that Danaher will post 3.99 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a dividend of $0.14 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.59%. Danaher’s payout ratio is 16.52%.

In other Danaher news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total value of $11,671,620.96. Following the sale, the chief executive officer now owns 271,737 shares in the company, valued at $25,173,715.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Insider Buying and Selling by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with's FREE daily email newsletter.